Histone deacetylase inhibitor suppression of autoantibody‐mediated arthritis in mice via regulation of p16INK4a and p21WAF1/Cip1 expression

Objective

To examine whether depsipeptide (FK228), a histone deacetylase (HDA) inhibitor, has inhibitory effects on the proliferation of synovial fibroblasts from rheumatoid arthritis (RA) patients, and to examine the effects of systemic administration of FK228 in an animal model of arthritis.

Methods

Autoantibody‐mediated arthritis (AMA) was induced in 19 male DBA/1 mice (6–7 weeks old); 10 of them were treated by intravenous administration of FK228 (2.5 mg/kg), and 9 were used as controls. The effects of FK228 were examined by radiographic, histologic, and immunohistochemical analyses and arthritis scores. RA synovial fibroblasts (RASFs) were obtained at the time of joint replacement surgery. In vitro effects of FK228 on cell proliferation were assessed by MTT assay. Cell morphology was examined by light and transmission electron microscopy. The effects on the expression of the cell cycle regulators p16^INK4a and p21^WAF1/Cip1 were examined by real‐time polymerase chain reaction and Western blot analysis. The acetylation status of the promoter regions of p16^INK4a and p21^WAF1/Cip1 were determined by chromatin immunoprecipitation assay.

Results

A single intravenous injection of FK228 (2.5 mg/ml) successfully inhibited joint swelling, synovial inflammation, and subsequent bone and cartilage destruction in mice with AMA. FK228 treatment induced histone hyperacetylation in the synovial cells and decreased the levels of tumor necrosis factor α and interleukin‐1β in the synovial tissues of mice with AMA. FK228 inhibited the in vitro proliferation of RASFs in a dose‐dependent manner. Treatment of cells with FK228 induced the expression of p16^INK4a and up‐regulated the expression of p21^WAF1/Cip1. These effects of FK228 on p16^INK4a and p21^WAF1/Cip1 were related to the acetylation of the promoter region of the genes.

Conclusion

Our findings strongly suggest that systemic administration of HDA inhibitors may represent a novel therapeutic target in RA by means of cell cycle arrest in RASFs via induction of p16^INK4a expression and increase in p21^WAF1/Cip1 expression.

     

The hypermethylation and protein expression of p16 INK4A and DNA repair gene O6-methylguanine-DNA methyltransferase in various uterine cervical lesions

Purpose This study is aimed at investigating the significance of gene promoter methylation status and protein expression of p16 ^INK4A and O⁶-methylguanine-DNA methyltransferase (MGMT) in the various uterine cervical lesions.Materials and methods Methylation status by using methylation-specific polymerase chain reaction (MS-PCR) and protein expression by using immunohistochemistry for p16 ^INK4A and MGMT genes were performed in cervical squamous intraepithelial neoplasms (CIN), invasive squamous cell carcinomas (SCC), adenocarcinomas and non-neoplastic cervices.Results None of 20 non-neoplastic cervices showed p16 ^INK4A and MGMT gene hypermethylation, whereas at least one of these genes was hypermethylated with 50.0% (5/10) of CIN I, 65.0% (13/20) of CIN II–III, 70.2% (33/47) of SCC and 85.0% (17/20) of adenocarcinoma. p16 ^INK4A protein was totally negative in non-neoplastic cervices, but positive with 90.0% of CIN I, 100% of CIN II–III and adenocarcinoma, and 78.7% of SCC. MGMT protein was expressed in 10% of non-neoplastic cervices, but significantly increased in SCC (42.5%) and adenocarcinoma (70.0%). The protein expression of p16 ^INK4A and MGMT was not related to their gene promoter methylation status.Conclusions The hypermethylation of p16 ^INK4A and MGMT genes in the uterine cervix may indicate the presence of malignant cells, and p16 ^INK4A immunostaining is useful in grading CIN and diagnosing invasive SCC and adenocarcinoma.     

Methylation status of p16INK4A tumor suppressor gene in Iranian patients with sporadic breast cancer

Introduction   p16 ^INK4A is a tumor suppressor encoding the Cdk inhibitor protein, which acts to repress Cdk4/6 and pRb phosphorylation. p16 ^INK4A gene can be inactivated by a variety of events, including promoter hypermethylation. Materials and methods  To investigate the methylation status of the p16 ^INK4A gene in Iranian patients with breast carcinoma, promoter methylation was studied by methylation-specific PCR (MSP) and restriction enzyme-related PCR (REP). In addition, p16 ^INK4A promoter was analyzed by PCR-SSCP in order to detection of mutation and single nucleotide polymorphisms. Results  Analysis of 70 patients by MPS and REP showed hypermethylation of p16 ^INK4A promoter in 35.7% (25/70) and 40% (28/70) of samples, respectively. Comparison of the molecular data and pathological information of the samples suggested that p16 ^INK4A gene might be inactivated at the early stages in breast cancer. Conclusion  Therefore, it could be suggested that hypermethylation of p16 ^INK4A promoter is one of the epigenetic factors affecting the progress of sporadic breast carcinogenesis in Iranian patients.     

Combination of SAHA and bortezomib up‐regulates CDKN2A and CDKN1A and induces apoptosis of Epstein‐Barr virus‐positive Wp‐restricted Burkitt lymphoma and lymphoblastoid cell lines

Epstein‐Barr virus (EBV) latent proteins exert anti‐apoptotic effects on EBV‐transformed lymphoid cells by down‐regulating BCL2L11 (BIM), CDKN2A (p16^INK4A) and CDKN1A (p21^WAF1). However, the potential therapeutic effects of targeting these anti‐apoptotic mechanisms remain unexplored. Here, we tested both in vitro and in vivo effects of the combination of histone deacetylase (HDAC) and proteasome inhibitors on the apoptosis of six endemic Burkitt lymphoma (BL) lines of different latency patterns (types I and III and Wp‐restricted) and three lymphoblastoid cell lines (LCLs). We found that the combination of HDAC and proteasome inhibitors (e.g. SAHA/bortezomib) synergistically induced the killing of Wp‐restricted and latency III BL and LCLs but not latency I BL cells. The synergistic killing was due to apoptosis, as evidenced by the high percentage of annexin V positivity and strong cleavage of PARP1 (PARP) and CASP3 (caspase‐3). Concomitantly, SAHA/bortezomib up‐regulated the expression of CDKN2A and CDKN1A but did not affect the level of BCL2L11 or BHRF1 (viral homologue of BCL2). The apoptotic effects were dependent on reactive oxygen species generation. Furthermore, SAHA/bortezomib suppressed the growth of Wp‐restricted BL xenografts in nude mice. This study provides the rationale to test the novel application of SAHA/bortezomib on the treatment of EBV‐associated Wp‐restricted BL and post‐transplant lymphoproliferative disorder.     

<Emphasis Type="Italic">p16</Emphasis><Superscript><Emphasis Type="Italic">INK4A</Emphasis></Superscript> Alterations are accompanied by aberrant protein immunostaining in endometrial carcinomas

Purpose To date, the significance of p16^INK4A tumor suppressor gene inactivation in sporadic endometrial cancer (EC) has only rarely been described. In this study, we examined the alteration type and frequency of gene alterations [point mutations, aberrant promoter methylation and loss of heterozygosity (LOH)] in 50 sporadic ECs, and correlated the genetic findings with the immunohistochemical expression of the p16^INK4A protein and the classical clinicopathological features.Methods Gene mutations were detected by PCR-SSCP-sequencing analysis, promoter hypermethylation by methylation-specific PCR (MSP), and LOH by PCR of the STS-marker c5.1.Results In total, p16^INK4A alterations were found in 14 of 50 (28%) sporadic ECs. In six (12%) cases, two alterations occurred simultaneously. Partial p16^INK4A deletions were found in four of 50 (8%) samples. There was one missense mutation (codon 70; CCCGCC) and one frameshift mutation (1-bp deletion in exon 2). Only 2 of 47 (4.2%) tumors exhibited aberrant promoter methylation. An allelic loss was detected in 12 of 50 (24%) carcinomas with a higher incidence in advanced endometrial carcinomas than in early-stage uterine tumors. p16^INK4A alterations were generally accompanied by gene silencing, confirmed by aberrant protein immunostaining (r=-0.442; P=0.001). There was a significant difference in the frequency of p16^INK4A alterations between early (stage I; 18%) and advanced (stages II–IV; 58%) ECs (P=0.022). One case showed complete protein loss, but absence of genetic alterations.Conclusions Our data indicate that p16^INK4A inactivation plays a role in the tumorigenesis of the subset of sporadic ECs, particularly in cases exhibiting an aggressive clinical behavior. We demonstrate that p16^INK4A methylation can act efficiently and similarly to other genetic alterations as one of the two necessary hits according to the Knudson two-hit hypothesis of tumor suppressor gene inactivation.     

DNA methylation analysis of tumor suppressor genes in monoclonal gammopathy of undetermined significance

Aberrant DNA methylation is considered an important epigenetic mechanism for gene inactivation. Monoclonal gammopathy of undetermined significance (MGUS) is believed to be a precursor of multiple myeloma (MM). We have analyzed methylation status of p15 ^INK4B , p16 ^INK4A , ARF, SOCS-1, p27 ^KIP1 , RASSF1A, and TP73 genes in bone marrow DNA samples from 21 MGUS and 44 MM patients, in order to determine the role of aberrant promoter methylation as one of the steps involved in the progression of MGUS to MM. Methylation specific polymerase chain reaction assay followed by DNA sequencing of the resulting product was performed. SOCS-1 gene methylation was significantly more frequent in MM (52%) than in MGUS (14%; p = 0,006). Methylation frequencies of TP73, ARF, p15 ^INK4B , p16 ^INK4A , and RASSF1A were comparable in MGUS: 33%, 29%, 29%, 5%, and 0%, to that observed in MM: 45%, 29%, 32%, 7%, and 2%. All patients lacked methylation at p27 ^KIP1 gene. In both entities, a concurrent methylation of p15 ^INK4B and TP73 was observed. The mean methylation index of MGUS was lower (0.16) than that of MM (0.24; p < 0.05). Correlations with clinicopathologic characteristics showed a higher mean age in MGUS patients with SOCS-1 methylated (p < 0.001); meanwhile in MM, methylation of p15 ^INK4B was more frequent in males (p = 0.009) and IgG isotype (p = 0.038). Our findings suggest methylation of TP73, ARF, p15 ^INK4B , and p16 ^INK4A as early events in the pathogenesis and development of plasma cell disorders; meanwhile, SOCS-1 methylation would be an important step in the clonal evolution from MGUS to MM.     

重组DNA甲基化酶1表达质粒对结肠癌细胞相关基因表达的影响

目的 分析DNA甲基化酶1(DNMT1)基因的真核表达质粒对人结肠癌细胞肿瘤相关基因的表达影响。方法 分别构建并转染含有人正义和反义DNMT1的真核表达质粒入结肠癌SW1116细胞，PCR和限制性内切酶证实转染结果，以Western印迹法分析各组细胞DNMT1蛋白的表达情况。定量PCR检测hMLH1、hMSH2及c—myc、p16^INK4A基因的表达。结果 经G418筛选得到稳定转染DNMT1基因的结肠癌细胞系，且分别在该转染有正义和反义质粒的细胞系中，DNMT1蛋白表达上调和下调。同时发现转染正义DNMT1的细胞中hMLH1、hMSH2及c—myc的表达降低，而转染反义DNMT1的细胞中hMSH2的表达明显增强。各组细胞p16^INK4A基因的表达差异不明显。结论 DNMT1基因调控人结肠癌细胞中肿瘤相关基因的表达。     

Analysis of p18INK4C in adult T-cell leukaemia and non-Hodgkin's lymphoma

p18^INK4C, a cyclin-dependent kinase inhibitor, is a homologue of p15^INK4B and p16^INK4A which are frequently altered in a variety of malignancies. We searched for structural alterations of the p18^INK4C gene in 44 adult T-cell leukaemias (ATLs), 101 non-Hodgkin's lymphomas (NHLs), two polyclonal B-cell proliferations, seven ATL cell lines and seven leukaemia/lymphoma cell lines, by Southern blot and polymerase chain reaction–single-strand conformation polymorphism (PCR-SSCP) analyses. No genomic alterations of the p18^INK4C gene were found in any of the samples. By RT-PCR, p18^INK4C was not expressed in three of five ATL cell lines, whereas it was expressed in all the non-ATL leukaemia/lymphoma cell lines. Tax did not inhibit the expression of p18^INK4C in tax-expressing Jurkat cells.     

MEK通路抑制剂对人胰腺癌细胞生长及细胞周期相关抑癌基因表达的影响

目的 观察细胞外信号调节激酶信号通路(MEK)抑制剂对人胰腺癌细胞生长及细胞周期相关的抑癌基因表达的影响。方法 培养人胰腺癌细胞系CFPAC1、PANC1和MiaPaCa2,应用50μmol/L的MEK抑制剂PD98059处理细胞24h,四甲基偶氮唑蓝(MTT)法检测细胞增殖,流式细胞仪分析细胞周期,实时定量PCR法检测p16INK4a、p21 WAF1和p27KIP1 mRNA的表达,蛋白质印迹法检测DNA甲基化酶(Dnmt)1、3a和3b表达,甲基化特异性PCR(MSP)分析p16INK4a基因启动子甲基化状况。结果 PD98059处理24h后,CFPAC1、PANC1和MiaPaCa2细胞的增殖抑制率分别为69％、78％和45％;G0/G1期细胞比例分别从(68.21±0.73)％、(56.54±0.68)％、(54.89±0.79)％增加到(80.37±0.65)％、(72.05±0.52)％、(79.21±0.93)％(P值均＜0.05);S期和G2/M期细胞比例相应减少。PD98059处理后,CFPAC1、PANC1细胞p27KIP1、p21WAF1和p16INK4a mRNA表达增加,Dnmt1和Dnmt3b蛋白表达减少;p16INK4a启动子甲基化状态被去除。而MiaPaCa2细胞仅p27KIP1 mRNA表达增加;p21WAF1、p16INK4a mRNA和Dnmt表达均无明显变化。结论 MEK通路抑制剂可能通过下调DNA甲基化酶、上调细胞周期相关抑癌基因表达而抑制胰腺癌细胞周期进展和细胞增殖。     

Trichostatin A, an inhibitor of histone deacetylase, inhibits smooth muscle cell proliferation via induction of p21(WAF1)

The proliferation of vascular smooth muscle cells (VSMCs) can contribute to a variety of pathological states, including atherosclerosis and post-angioplasty restenosis. The p21(WAF1) cyclin-dependent kinase inhibitor regulates cell-cycle progression, senescence, and differentiation in injured blood vessels. Histone deacetylase (HDAC) inhibitors have shown utility in controlling proliferation in a wide range of tumor cell lines, possibly by inducing the expression of p21(WAF1). Our goal was to investigate the effect of trichostatin A (TSA), a specific and potent HDAC inhibitor, on the proliferation of vascular smooth muscle cells (VSMCs) isolated from rat thoracic aorta. TSA suppressed the HDAC activity of VSMCs in a dose-dependent manner and inhibited VSMC proliferation as demonstrated by cell number counting and the degree of [3H] thymidine incorporation. Further, TSA reduced the phosphorylation of Rb protein, a regulator of cell-cycle progression. TSA treatment also induced the expression of p21(WAF1) but not of p16(INK4), p27(KIP1) or p53. Finally, TSA inhibited HDAC activity of VSMCs from p21(WAF1) knock-out mice but had no effect on VSMC proliferation in these animals. In conclusion, TSA inhibits VSMC proliferation via the induction of p21(WAF1) expression and subsequent cell-cycle arrest with reduction of the phosphorylation of Rb protein at the G1-S phase.     

Expression of p16<Superscript>INK4A</Superscript> gene in human pituitary tumours

Pituitary adenomas comprise 10–15% of primary intracranial tumours but the mechanisms leading to tumour development are yet to be clearly established. The retinoblastoma pathway, which regulates the progression through the cell cycle, is often deregulated in different types of tumours. We studied the cyclin-dependent kinase inhibitor p16^INK4A gene expression at mRNA level in human pituitary adenomas. Forty-six tumour specimens of different subtypes, 21 clinically non-functioning, 12 growth hormone-secreting, 6 prolactin-secreting, 6 adrenocorticotropin-secreting, and 1 thyrotropin-secreting tumours were studied. All clinically non-functioning and most of the hormone-secreting tumours were macroadenomas (38/46). The RT–PCR assay and electrophoresis of the PCR-products showed that p16^INK4A mRNA was undetectable in: 62% of non-functioning, 8% of growth hormone-secreting, 17% of prolactin-secreting and 17% of adrenocorticotropin-secreting adenomas. Forty percent of all macroadenomas and 25% of microadenomas had negative p16^INK4A mRNA, the latter results suggest that the absence of p16^INK4A product might be an early event in tumours with no expression of this suppressor gene. Within the non-functioning adenomas 63% were “null cell” and 37% were positive for some hormone, both subgroups showed similar percentage of cases with absence of p16^INK4A mRNA. Our results show that clinically non-functioning macroadenomas have impaired p16^INK4A expression in a clearly higher proportion than any other pituitary tumour subtype investigated. Other regulatory pathways may be implicated in the development of tumours with positive p16^INK4A expression.     

p16INK4/p15INK4B gene inactivation is a frequent event in malignant T-cell lines

Abstract: The cell cycle regulators p16^INK4 and p15^INK4B have been mapped to the minimal region of overlap for chromosome 9p21 deletions, observed in a number of malignancies, suggesting that they could be tumor suppressor genes (TSGs). In the case of pl6^INK4 this has been further substantiated by the finding of small intragenic mutations. In this study we have investigated the p16^INK4 and p15^INK4B genes in 16 malignant T-cell lines by means of Southern blot, PCR and sequence analysis. p16^INK4 allelic deletions occurred in 15 of 16 cell lines; 12 of which were homozygous and 3 hemizygous. In 1 cell line (DND 41) the remaining p16^INK4 allele carried a microdeletion of 29 bp of exon 2, supporting the concept that p16^INK4 is a target TSG for deletions on 9p21. Most p16^INK4 deletions also included the p15^INK4B gene. However, 4 of the cell lines deleted for p16^INK4 showed no evidence of p15^INK4B loss, indicating that p15^INK4B is not the target in these cell lines.